2-acetyl-3-hydroxy-6-nitro-1H-inden-1-one | 296793-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 2-acetyl-3-hydroxy-6-nitro-1H-inden-1-one
• 英文别名: 2-acetyl-3-hydroxy-5-nitroinden-1-one
• CAS: 296793-85-6
• 化学式: C11H7NO5
• 分子量: 233.18
• InChiKey: MWUCMXGVNLRNJM-UHFFFAOYSA-N

物化性质

• 沸点：
  479.8±45.0 °C(Predicted)
• 密度：
  1.615±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• METHODS OF IDENTIFYING HIT-ANTIBODIES AND PF4 ANTAGONISTS AND CELL LINES FOR USE THEREIN
  申请人：The Trustees of The University of Pennsylvania

  公开号：EP2828658B1

  公开（公告）日：2017-06-14
• [EN] SMALL MOLECULE ANTAGONISTS OF PF4 CONTAINING ULTRA LARGE COMPLEXES<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE PF4 CONTENANT DES COMPLEXES ULTRA-LARGES
  申请人：TRUSTEES OF THE UNIVERSITY OF PENSYLVANIA

  公开号：WO2013142328A1

  公开（公告）日：2013-09-26

  Methods for preventing formation of or disrupting PF4 tetramers are provided. The compounds useful in such methods bind to a PF4 tetramer, dimer, or monomer. The compounds are also useful for preventing formation of or disrupting ultra-large complexes containing a PF4 tetramer and a glycosaminoglycan, and thus have utility toward preventing or treating medical conditions related to the formation of PF4 tetramers, such as HITT and atherosclerosis and toward correcting a platelet imbalance, preventing a decrease in platelet production and increasing high density lipoproteins in a subject. Also provided are compositions and kits containing these compounds and optional medications which cause the formation of PF4 tetramers, and/or medications which disrupt PF4 tetramers. [Formula I]
• [EN] METHODS OF IDENTIFYING HIT-ANTIBODIES AND PF4 ANTAGONISTS AND CELL LINES FOR USE THEREIN<br/>[FR] MÉTHODES D'IDENTIFICATION D'ANTICORPS HIT ET D'ANTAGONISTES PF4 ET LIGNÉES CELLULAIRES UTILISABLES À CET EFFET
  申请人：UNIV PENNSYLVANIA

  公开号：WO2013142330A1

  公开（公告）日：2013-09-26

  Methods and cells or cell lines for identifying antibodies or fragments thereof that activate heparin-induced thrombocytopenia (HIT) are described. The methods comprise contacting a hematopoietic cell or cell line that comprises, in operative association, the platelet receptor FcyRIIA under the control of a suitable promoter, and a reporter construct comprising a reporter gene under the control of a promoter and transcription factor, which transcription factor is regulated downstream of the signaling cascade of activated FcyRIIA, with a test sample from a mammalian subject; a platelet factor 4 (PF4), a wild-type or variant of PF4 or a fragment thereof; and heparin; and detecting or measuring the level of reporter gene expression.